Unravelling the Politics Behind India’s PM-JAY Health Insurance Scheme

By HEOR Staff Writer

July 26, 2023

The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.

Reference url

Recent Posts

NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...